Report Highlights
The global market for companion diagnostics reached nearly $3.2 billion in 2015. This market is expected to increase from $4.3 billion in 2016 to nearly $17.6 billion in 2021 at a compound annual growth rate (CAGR) of 32.3% for 2016-2021.
Report Includes
- An overview of the market for companion diagnostics, including existing products on the market and detailed analysis of the competitive environments.
- Analyses of market trends, with data from 2015 and 2016, and projections of compound annual growth rates (CAGRs) through 2021.
- Examination of the current state of the industry, new technologies in assay development, and potential novel commercial venues in this area of the healthcare industry.
- Identification of major commercial sectors in companion diagnostics: oncology related products vs. cardiovascular diseases and other segments.
- Profiles of major players as well as a list of current companies that have new companion diagnostics products in development.
Report Scope
The scope of the report encompasses the major types of diagnostics technologies that have been used, the various industry structures such as the lab developed tests (LDTs) sector, and the major applications being commercialized and developed by a wide range of company types. It analyzes current market status, examines future market drivers and presents forecasts of growth over the next five years. Technology developments, including the latest trends, are discussed.
Analyst Credentials
Robert Hunter is a senior management consultant, commercialization consultant and technology and market analyst with over 20 years of experience in life sciences and healthcare. Recent consulting includes market/technology analysis and forecasting of customer adoption and revenue for a high content screening (HCS) technology leader. He is an early investor in a company using stem cells for predictive drug safety testing in vitro. He has a B.S. in Mechanical Engineering from Clemson University and Master of Business Administration from The Tuck School of Business at Dartmouth.
Related Reports
Epigenetics: Technologies and Global Markets
The global market for epigenetics research tools and reagents, IVDs and therapeutics is expected to grow from $4.8 billion in 2024 to $8.5 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.8% from 2024 through 2029.
High-Throughput Screening: Technologies and Global Markets
The global market for high-throughput screening (HTS) is expected to grow from $23.8 billion in 2024 to $39.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 10.5% from 2024 through 2029.
In Vitro Diagnostics: Technologies and Global Markets
The global market for In Vitro Diagnostics (IVD) is expected to grow from $94.7 billion in 2024 and is projected to reach $141.9 billion by the end of 2029, at a compound annual growth rate (CAGR) of 8.4% during the forecast period of 2024 to 2029.
High Content Screening/Imaging: Technologies and Global Markets
The global market for high content screening and imaging (HCS/I) is estimated to increase from $3.4 billion in 2024 to reach $5.1 billion by 2029, at a compound annual growth rate (CAGR) of 8.4% from 2024 through 2029.
Track the Latest Global Tariff Developments
In today's fast-paced global economy, tariffs are no longer static—they are dynamic levers shaped by geopolitical realignments, supply chain vulnerabilities, inflationary pressures, and sustainability-driven trade reforms. As governments worldwide recalibrate their trade strategies, businesses are left to navigate a maze of shifting rules, rising costs, and regulatory uncertainty.
Our analysis empowers you with real-time updates and in-depth expert analysis on all facets of global tariff activity. From new trade agreements and sanctions to abrupt tariff hikes and retaliatory duties, we monitor developments across borders, sectors, and industries—so you don't have to.
Whether it's the ongoing U.S.–China trade dynamics, the evolving EU Carbon Border Adjustment Mechanism (CBAM), or the emerging policies in India, ASEAN, and Latin America, we provide full-spectrum coverage. We also track multilateral trade negotiations, World Trade Organization (WTO) rulings, and sector-specific duty structures—ensuring you are always ahead of global trade shifts.
With our analysis, you can stay informed, identify risks, and confidently respond to tariff changes—no matter where you operate.
Ready to see what tariff means for your business?
Consult with our experts or request your custom Tariff Impact Brife today
Stay Informed, Stay Competitive
In today's interconnected and unpredictable global economy, staying ahead of tariff shifts is not just important—it's essential. BCC Research provides decision-makers with trusted, research-driven insights that turn uncertainty into opportunity.
Our in-depth market analysis and trade intelligence help you decode how tariff changes impact your specific sector—manufacturing, healthcare, technology, agriculture, or energy. We break down complex data into actionable knowledge through comprehensive reports, expert commentaries, and sector-focused forecasts.
Our analysis includes:
- Thorough breakdowns of current and proposed tariff policies and how they affect regional and global trade flows.
- Sector-specific implications, helping you understand the strategic impact on sourcing, pricing, and competitiveness.
- Forward-looking insights to support risk management, planning, and response strategies for evolving trade conditions.
With BCC Research, you gain more than just information—you gain clarity and confidence to make well-informed decisions in a volatile trade environment.
Don't let tariffs catch you off guard—let our insights guide your strategy.
Recent Reports
Global Cell Line and Membrane Market
The global market for cell lines and membranes was valued at $5.7 billion in 2024 and is estimated to increase from $6.3 billion in 2025 to reach $11.4 billion by 2030, at a compound annual growth rate (CAGR) of 12.5% from 2025 through 2030.
Human Microbiome-based Drugs and Diagnostics: Global Markets
The global market for human microbiome-based drugs and diagnostics is expected to grow from $393.4 million in 2025 to reach $1.2 billion by the end of 2030, at a compound annual growth rate (CAGR) of 25.6% from 2025 through 2030.
Global Microbiome Sequencing Market
The global microbiome sequencing market is expected to grow from $1.5 billion in 2024 and is projected to reach $3.7 billion by the end of 2029, at a compound annual growth rate (CAGR) of 19.3% during the forecast period of 2024 to 2029.
Proteomics: Technologies and Global Markets
The global market for proteomic technologies was valued at $27.6 billion in 2024. It is projected to grow from $31.0 billion in 2025 to $57.2 billion by the end of 2030, at a compound annual growth rate (CAGR) of 13.0% from 2025 to 2030.
Biologic Therapeutic Drugs: Technologies and Global Markets
The global market for biologic therapeutic drugs is estimated to increase from $499.2 billion in 2024 to reach $794.5 billion by 2029, at a compound annual growth rate (CAGR) of 9.7% from 2024 through 2029.
Top Trending Reports
Biologic Therapeutic Drugs: Technologies and Global Markets
The global market for biologic therapeutic drugs is estimated to increase from $499.2 billion in 2024 to reach $794.5 billion by 2029, at a compound annual growth rate (CAGR) of 9.7% from 2024 through 2029.
Next-Generation Advanced Batteries: Global Markets
The global market for next-generation advanced batteries is estimated to grow from $1.5 billion in 2024 to reach $5.3 billion by the end of 2029, at a compound annual growth rate (CAGR) of 28.5% from 2024 through 2029.
Global Pharmaceutical Drugs Industry: Competitive Landscape 2023
This report discusses the global pharmaceutical drugs industry and its competitive landscape in terms of significant player market ranking and top pharmaceutical drugs. Company profiles of the top 50 pharmaceutical companies, innovative products and technologies, trends and market dynamics, competitive intelligence, and regional trends are well-researched and analyzed in this report.
Global Markets and Manufacturing Technologies for Protein Drugs
The global protein drugs market is expected to grow from $441.7 billion in 2024 and is projected to reach $655.7 billion by the end of 2029, at a compound annual growth rate (CAGR) of 8.2% during the forecast period of 2024 to 2029.
Global Markets for Emerging Medical Device Technologies
The global market for emerging medical devices is estimated to increase from $136.6 billion in 2024 to reach $223.9 billion by 2029, at a compound annual growth rate (CAGR) of 10.4% from 2024 through 2029.
Report Highlights
The global companion diagnostics market reached $1.1 billion in 2012. The market is expected to grow to $1.2 billion in 2013 and $3.5 billion in 2018 with a compound annual growth rate (CAGR) of 23.9%.
Report Includes
- An overview of the market for companion diagnostics, including existing products on the market and detailed analysis of the competitive environments.
- Analyses of market trends, with data from 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018.
- Examination of the current state of the industry, new technologies in assay development, and potential novel commercial venues in this area of the healthcare industry.
- Identification of major commercial sectors in companion diagnostics: oncology related products vs. cardiovascular diseases and other segments.
- Comprehensive company profiles of major players, as well as a list of current companies that have new companion diagnostics products in development.
Report Highlights
-
Oncotype Dx, although not FDA-approved, is still a lead product in the breast cancer diagnosis sector. Oncotype Dx is reimbursed by most insurance companies and therefore enjoys an increase in its sales number every year. Valued at $170 million in 2010, analysts believe that by 2015, Oncotype Dx for breast cancer risk recurrence and drug regimen may reach $300 million, a compound annual growth rate (CAGR) of 12%.
-
The approval of Selzentry for first time HIV patients is creating new opportunity for the assay Trofile, a companion diagnostic to Selzentry (Celsentri outside U.S.). As a result, Trofile is expected to reach an estimated $34 million by 2015, from $24 million in 2010, a compound annual growth rate (CAGR) of 7.2%.
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More